Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks [Yahoo! Finance]
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
Regeneron Announces Investor Conference Presentations
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $925.00 price target on the stock.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call Transcript [Yahoo! Finance]